In a historic stride for global health, Ugandan scientists are earning international acclaim for their pivotal role in the development of Lenacapavir—a long-acting HIV prevention injection that requires just two doses per year. This revolutionary advancement promises to redefine how the world approaches HIV prevention, and at its heart are a dedicated team of Ugandan researchers.
Unlike traditional daily oral PrEP, Lenacapavir offers six months of protection from a single shot, marking a significant shift in HIV prevention strategies, especially for populations facing challenges with daily medication adherence.
Uganda at the Helm of Global Health Innovation
The scientific trailblazers behind Uganda’s contribution include:
Dr. Flavia Matovu Kiwewa, Clinical Researcher at the Makerere University, Johns Hopkins University Research Collaboration (MU-JHU), highlighted the practical impact: “For many at-risk Ugandans, taking a pill every day isn’t always feasible. This injection brings prevention closer to real-life needs.”
Prof. Noah Kiwanuka, Professor of Epidemiology and Biostatistics at Makerere University School of Public Health, underscored Africa’s rising leadership in science: “This is proof that African researchers are not just participants but leaders in developing solutions tailored to our communities.”
Dr. Godfrey Kigozi, Senior Scientist with the Rakai Health Sciences Program, emphasized community involvement: “The trust and participation of local communities in Rakai were instrumental. Their contribution made this global milestone possible.”
Dr. Clemesia Nakabiito, Senior Consultant Obstetrician and Gynecologist at Mulago National Referral Hospital, brought focus to women’s inclusion: “Women face disproportionate risk. Ensuring their involvement in this trial was not just necessary, it was foundational.”
Global Endorsements for a Made-in-Uganda Milestone
The achievement has drawn widespread praise from global health leaders. Winnie Byanyima, Executive Director of UNAIDS, hailed Lenacapavir as “a game-changer that could revolutionize HIV prevention, especially for women and young people in Africa who often struggle with stigma and daily medication access.”
Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), echoed the sentiment, stating: “This innovation exemplifies the power of inclusive science. Uganda’s role proves that African leadership is central to solving global health challenges.”
A Turning Point for Uganda and the World
Uganda, long recognized as a key battleground in the global HIV epidemic, now stands as a beacon of scientific leadership. The country’s data and trial outcomes have informed global regulatory decisions and demonstrated that Africa can lead high-impact biomedical innovation, not just for the continent, but for the world.
The rollout of Lenacapavir brings renewed hope for millions: reducing new HIV infections, minimizing stigma, and easing the psychological and logistical burdens of daily prevention regimens.
As Lenacapavir begins its journey into clinics and communities worldwide, Uganda can take pride in a profound truth: the fight against HIV has a new weapon, and it carries the fingerprints of Ugandan science and solidarity.
